The full year adjusted effective tax rate in the range of 22% to 23%, up from 21% to 22%.
Net loss was $10.6 million or $0.27 per share versus net income of $2.2 million or $0.06 per diluted share.
In total, we anticipate cost savings approximately $20 million annually.
We also have more than 20 products in development and expect to add more from both external and internal efforts.
The plan is expected to be completed in approximately 18 months and generate annual cost savings of approximately $20 million.
Gross profit was $20.6 million or 20% of net sales compared with $34.4 million or 27% of net sales for the prior year first quarter.
For fiscal 2022, we now expect net sales in the range of $370 million to $400 million, down from $400 million to $440 million.
We have revised down our fiscal 2022 guidance to reflect the increasingly competitive environment for a base oral generics portfolio.
So with that, let's turn to the restructuring and cost reduction plan we announced earlier today.
Again, our plan retains our core strategies while further optimizing our operations, improving efficiencies and reducing costs.
The plan will be implemented in phases, and we expect we will be completed in about 18 months.
The plan is expected to be completed in approximately 18 months and generate annual cost savings of approximately $20 million.
And lastly, capital expenditures to be approximately $10 million to $14 million, down from $12 million to $18 million.
This includes reducing headcount and eliminating development formerly dedicated to the Carmel site and discontinuing future development programs targeting liquid generic medications as we no longer see adequately scaled returns in that sector.
Ultimately, the plan is expected to result in a workforce reduction of approximately 11% from current levels.
In total, we anticipate cost savings approximately $20 million annually.
We also have more than 20 products in development and expect to add more from both external and internal efforts.
The plan is expected to be completed in approximately 18 months and generate annual cost savings of approximately $20 million.
Gross profit was $20.6 million or 20% of net sales compared with $34.4 million or 27% of net sales for the prior year first quarter.
